JDD August 2023 Issue Highlights | Special Focus: Psoriasis
With a special focus on the topic of psoriasis, check out highlights from the August issue of the Journal of Drugs in Dermatology (JDD) straight from the JDD Editor’s desk:
Consensus Statements on the Use of Corticosteroid-Containing Topical Medications in Psoriasis delves into the expert guidance provided by the Psoriasis Expert Group (PEG), encompassing nine crucial statements that offer com …
With a special focus on the topic of psoriasis, check out highlights from the August issue of the Journal of Drugs in Dermatology (JDD) straight from the JDD Editor’s desk:
Consensus Statements on the Use of Corticosteroid-Containing Topical Medications in Psoriasis delves into the expert guidance provided by the Psoriasis Expert Group (PEG), encompassing nine crucial statements that offer com … Continue reading "JDD August 2023 Issue Highlights | Special Focus: Psoriasis"
Next Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Amit Garg, professor and founding chairman of the department of dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Dr. Garg explains why it’s an exciting time in hidradenitis suppurativa, and how clinicians are using existing therapies in innovative ways. Watch as he explains the imp … 
Apremilast (OTEZLA®) is a twice daily oral medication that is FDA approved for adults with plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behçet’s Disease.1 This drug is being extended as an off-label treatment to target inflammation in a number of different conditions. This Therapeutic Cheat Sheet will focus on apremilast and its applications for different dermatologica … 
Upadacitinib (RINVOQ®) is a once daily oral medication that is FDA approved for a variety of conditions including psoriatic arthritis and atopic dermatitis. Jak inhibitors, like upadacitinib, are a class of drugs showing to be effective in treating inflammatory conditions. Upadacitnib is not only being used to treat rheumatoid arthritis and psoriatic arthritis, but was recently FDA approved i … 
Androgenic alopecia (AGA) is one of the most common forms of hair loss and represents a frequently faced disabling concern in dermatology visits. Targeting the 5α-dihydrotestosterone (DHT) pathway has been shown to be an efficacious mechanism of action, with finasteride being the only systemic FDA-approved drug to treat male AGA. Recently, its sister drug, dutasteride, has been increasingly utili …